Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, et al. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 2024;147:107602.
PMID: 39461095